Inhalable responsive polysaccharide-based antibiotic delivery nanoparticles to overcome mucus barrier for lung infection treatment
Hui‐Min Ren(Beijing University of Chemical Technology), Fu‐Jian Xu(Beijing University of Chemical Technology), Fei Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Chengyue Lei(Beijing University of Chemical Technology), Lin Han(Beijing University of Chemical Technology), Zongpeng Xiu(Beijing University of Chemical Technology), Lujiao Zhang(Beijing University of Chemical Technology), Shun Duan(Beijing University of Chemical Technology), Bingran Yu(Beijing University of Chemical Technology), Yuqing Zhao(Beijing University of Chemical Technology), Nana Zhao
Cited by 56
Related Papers
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
|The Lancet|2020|29.1k
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
|New England Journal of Medicine|2020|5.5k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Biomedical polymers: synthesis, properties, and applications
|Science China Chemistry|2022|187